KingMed Diagnostics   Report issue

For profit Phase 1
Founded: Guangzhou China (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2018
NCT03550508
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

KingMed Diagnostics

Active Ingredients

Drugs in Phase 1 Trials (1)

jmt103 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Marrow Diseases (Phase 1)

Bone Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms, Second Primary (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1